PAVmed Inc. Series Z Warrant - PAVMZ STOCK NEWS

Welcome to our dedicated page for PAVmed Series Z Warrant news (Ticker: PAVMZ), a resource for investors and traders seeking the latest updates and insights on PAVmed Series Z Warrant stock.

PAVmed Inc. Series Z Warrant (symbol: PAVMZ) is a diversified commercial-stage medical technology company focused on developing innovative medical devices, diagnostics, and digital health solutions. Led by accomplished medical device entrepreneurs, the company aims to address unmet clinical needs by swiftly advancing a pipeline of cutting-edge products. PAVmed operates in three primary segments: Diagnostics, Medical Devices, and Digital Health. Its flagship products include EsoGuard, esocheck, and the Veris Cancer Care Platform, offering revolutionary solutions for cancer prevention and personalized care.

05/02/2024 08:35 AM

News

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 13, 2024

Rhea-AI Summary

Lucid Diagnostics, a cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc., will hold a business update conference call and webcast on May 13, 2024, at 8:30 AM ET. The call will feature Lucid's CEO providing an operational overview and growth strategy, along with the CFO discussing first-quarter 2024 financial results. Investors can access the webcast on the company's website or join via telephone.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.08%

Tags

04/08/2024 08:30 AM

News

Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Lucid Diagnostics Inc. (LUCD) announced that their President & COO will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference. The webcast will be available on their website, with a replay option for 30 days.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.48%

Tags

03/26/2024 07:32 PM

News

PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary

PAVmed Inc. reports a 33% sequential increase in quarterly revenue and launches PMX incubator for technology development. Lucid Diagnostics Inc. shows revenue growth and expansion in clinical data evidence. Veris Health Inc. focuses on financing from academic and regional cancer centers. Financially, the company had a net loss but positive revenue growth.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/25/2024 05:30 PM

News

Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results

Rhea-AI Summary

Lucid Diagnostics Inc. (LUCD) reports a 33% sequential increase in Quarterly EsoGuard® revenue. The company is focused on expanding clinical validity and utility data to drive medical policy coverage, including potential Medicare coverage. Lucid's recent business update highlights revenue growth, stable test volume, improving revenue cycle management, and progress in engaging with major commercial payors for positive coverage.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-6.6%

Tags

03/21/2024 09:30 AM

News

Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population

Rhea-AI Summary

Lucid Diagnostics Inc. announces promising results from a VA screening study showing EsoGuard sensitivity of 92.9% and negative predictive value of 98.6% for esophageal precancer detection. The study highlights EsoGuard as a powerful screening tool for early detection of esophageal cancer.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

03/20/2024 08:30 AM

News

Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference

Rhea-AI Summary

Lucid Diagnostics Inc. (LUCD) and collaborators will present data on three studies on EsoGuard® esophageal precancer testing and one on a new genetic classifier of esophageal neoplasia at the Digestive Disease Week (DDW) Annual Meeting 2024. The studies aim to expand the clinical evidence base for EsoGuard testing to detect esophageal precancer and introduce a new genetic classifier.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.78%

Tags

03/13/2024 08:30 AM

News

PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024

Rhea-AI Summary

PAVmed Inc. to host a business update conference call and webcast to discuss operations, growth strategy, and financial results for the fourth quarter and full year 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-13.6%

Tags

03/12/2024 08:30 AM

News

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26, 2024

Rhea-AI Summary

Lucid Diagnostics Inc. (Nasdaq: LUCD) announced a business update conference call and webcast to discuss operational updates, growth strategy, and financial results for the fourth quarter and full year 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

02/16/2024 05:00 PM

News

Lucid Diagnostics Provides Update Regarding World Trade Center Health Program

Rhea-AI Summary

Lucid Diagnostics Inc. (Nasdaq: LUCD) received notification from the World Trade Center Health Program regarding a clerical error in listing the EsoGuard® Esophageal DNA test as a covered benefit. Lucid is actively engaging with Clinical Centers of Excellence to rectify the issue and ensure access to esophageal precancer testing for at-risk participants.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.41%

Tags

02/15/2024 07:45 AM

News

Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony

Rhea-AI Summary

Lucid Diagnostics Inc. highlights EsoCheck's advanced cell collection technology during testimony before the U.S. House of Representatives' Committee on Small Business. EsoCheck's innovative Collect & Protect® technology offers precise, noninvasive esophageal cell collection, leading to unprecedented early precancer detection results. The device's efficiency allows for high-volume testing events, with excellent patient satisfaction and DNA yields. In contrast, older 'sponge-on-a-string' technologies lack EsoCheck's precision and protection features, resulting in poor sensitivity and mechanical failures.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.24%

Tags

FAQ

What is the current stock price of PAVmed Series Z Warrant (PAVMZ)?

The current stock price of PAVmed Series Z Warrant (PAVMZ) is $0.0275 as of November 18, 2024.

What is PAVmed Inc.'s main focus?

PAVmed Inc. is primarily focused on developing innovative medical devices, diagnostics, and digital health solutions to address unmet clinical needs.

What are some of PAVmed Inc.'s key products?

Some of PAVmed Inc.'s flagship products include EsoGuard, esocheck, and the Veris Cancer Care Platform.

Who leads PAVmed Inc. Series Z Warrant?

PAVmed Inc. Series Z Warrant is led by accomplished medical device entrepreneurs with a vision to enhance healthcare through cutting-edge technologies.

In what segments does PAVmed Inc. operate?

PAVmed Inc. operates in three primary segments: Diagnostics, Medical Devices, and Digital Health, offering a diversified portfolio of medical technologies.

What sets PAVmed Inc. apart from other medical technology companies?

PAVmed Inc. stands out for its focus on capital and time efficiency, swiftly advancing a diverse pipeline of innovative products to meet evolving clinical needs.